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Prefrontal Cortical Gamma-Aminobutyric Acid Levels in Panic
Disorder Determined by Proton Magnetic Resonance
Spectroscopy
Abstract
BACKGROUND: Panic disorder (PD) is hypothesized to be associated with altered function of the
major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Previous proton magnetic
resonance spectroscopy (MRS) studies found lower GABA concentrations in the occipital cortex of
subjects with PD relative to healthy control subjects. The current study is the first MRS study to
compare GABA concentrations between unmedicated PD subjects and control subjects in the prefrontal
cortex (PFC). METHODS: Unmedicated subjects with PD (n = 17) and age- and sex-matched healthy
control subjects (n = 17) were scanned on a 3 Tesla scanner using a transmit-receive head coil that
provided a sufficiently homogenous radiofrequency field to obtain spectroscopic measurements in the
dorsomedial/dorsal anterolateral and ventromedial areas of the PFC. RESULTS: The prefrontal cortical
GABA concentrations did not differ significantly between PD subjects and control subjects. There also
was no statistically significant difference in glutamate/glutamine (Glx), choline, or N-acetyl aspartate
concentrations. CONCLUSIONS: The previously reported finding of reduced GABA concentrations in
the occipital cortex of PD subjects does not appear to extend to the PFC.
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ABSTRACT 
Background: Panic disorder (PD) is hypothesized to be associated with altered function of 
the major inhibitory neurotransmitter, gamma-amino butyric acid (GABA). Previous proton 
magnetic resonance spectroscopy (MRS) studies found lower GABA concentrations in the 
occipital cortex of subjects with PD relative to healthy controls. The current study is the first 
MRS study to compare GABA concentrations between unmedicated PD subjects and controls 
in the prefrontal cortex (PFC).  
Methods: Unmedicated subjects with PD (n=17) and age- and sex-matched healthy controls 
(n=17) were scanned on a 3 Tesla scanner using a transmit-receive head coil that provided a 
sufficiently homogenous radiofrequency field to obtain spectroscopic measurements in the 
dorsomedial/dorsal anterolateral and ventromedial areas of the PFC.  
Results: The prefrontal cortical GABA concentrations did not differ significantly between PD 
subjects and controls. There also was no statistically significant difference in Glx, choline or N-
acetyl-aspartate concentrations. 
Conclusions: The previously reported finding of reduced GABA concentrations in the occipital 
cortex of PD subjects does not appear to extend to the PFC.  
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Introduction 
Panic disorder (PD) is hypothesized to be associated with altered function of the major 
inhibitory neurotransmitter, gamma-amino butyric acid (GABA)(1). Goddard et al(2) initially 
applied MRS to assess brain GABA concentrations in the occipital lobe of PD patients, and 
found that GABA levels were reduced in 12 of 14 unmedicated PD subjects (2). Another 
study found decreased GABA levels in the anterior cingulate cortex and basal ganglia of 
medicated PD subjects(3). Based upon these results, we hypothesized that GABA levels 
would be reduced in the prefrontal cortex in unmedicated PD subjects versus controls. 
In vivo proton MRS is a valid tool for studying the concentrations of abundant 
neurotransmitters in brain disorders(4,5). Because of the relatively low sensitivity of the 
imaging method, MRS spectra were acquired from two large voxels with a long scan time 
(27min per voxel). Based on benzodiazepine receptor studies in PD(6) one voxel was 
positioned in the dorsomedial/anterolateral PFC (DM/DALPFC); based on 
neurophyisiological imaging studies in PD(1) a second voxel was positioned in the 
ventromedial PFC (VMPFC).  
 
Methods and Materials 
Participants between 18 and 60 years met DSM-IV criteria for PD [n=17, 12 female, 
mean age=34.2+10.1 years (range 21-55)]. Healthy control subjects with no history of any 
psychiatric disorder and no major psychiatric condition in first-degree relatives were matched 
for age and gender to the PD subjects [n=17, 12 female; mean age=35.1+11.8 years (range 19-
58). Diagnosis was established by the Structured Clinical Interview for DSM-IV and 
confirmed by an unstructured interview with a psychiatrist. Exclusion criteria included major 
medical illnesses, pregnancy, psychotropic drug exposure (including nicotine and excessive 
alcohol consumption) within 3 months, lifetime history of substance abuse and dependence, 
psychiatric disorders other than PD, other anxiety disorders and MDD, structural brain 
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abnormalities on MRI, or general MRI exclusions. Subjects were asked to abstain from 
alcohol within the 24 hours prior to scanning. The severity of panic, anxiety and depressive 
symptoms was assessed using the Panic Disorder Severity Scale (PDSS), the Panic Symptom 
Scale (PSS), the Hamilton Anxiety Scale (HAS) and the 21-item Hamilton Depression Rating 
Scale (HDRS). Written informed consent was obtained as approved by the NIMH IRB.  
The methods for obtaining the MRS measures were identical to those used in our 
previous GABA-MRS studies, as detailed elsewhere(7). Subjects were scanned (between 
9/2004-11/2005) in a single session on a 3 Tesla GE scanner using a GE transmit-receive head 
coil capable of providing a homogenous radiofrequency field and spectroscopic measurements 
from prefrontal cortical tissue. Proton MRS spectra were acquired from two voxels: the 
DM/DALPFC voxel (5x3x2cm) and the VMPFC voxel (3x3x2cm). For more details see 
footnote of table 1.  
 GABA was measured using an interleaved PRESS-based J editing method(8,9). The 
concentrations of GABA, choline, N-acetyl aspartate (NAA), and co-edited Glx (i.e., 
glutamate and glutamine) were expressed in mmol/liter (mM) referenced to concentration of 
creatine that was found to be normal in the medial prefrontal cortex of PD subjects(10). 
Creatine was set to 7.1 mmol/L, a value which constituted the average concentration from 
literature reports of creatine in gray and white matter(11,12). This conventional creatine 
referencing method has been used previously(13,14), and its application in the current study 
was supported by previously published data showing no difference in the medial PFC creatine 
levels between PD subjects and healthy controls(10). Gray matter fraction was derived from 
segmentation based on a histogram of anatomical image intensities. 
The hypothesis that GABA concentrations in the VMPFC and DM/DALPFC would be 
reduced in PD subjects versus controls was tested using paired two-tailed t-tests. Because we 
tested this hypothesis in two regions, the significance threshold was set at a Bonferroni-
adjusted significance level of p=0.025.  
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Results 
 In the PD group the mean age at PD onset was 22+8.9 years, mean duration of PD was 
108+120 months, and mean time medication free was 21+31 months (range 3-96 months; 9 
subjects were drug-naïve). Seven PD subjects had comorbid MDD, seven had comorbid 
agoraphobia and three had a comorbid phobic disorder. The mean PDSS score was 7.5+3.0, 
the mean PSS score was 18+5.4, the mean HAS score was 9.6+6.2, and the mean HDRS score 
was 9.6+7.4. 
 The concentrations of GABA, Glx, choline, and NAA did not differ significantly 
between PD subjects and controls in either the DM/DALPFC or the VMPFC (table 1). The 
gray matter fraction was reduced in PD subjects relative to controls in the DM/DALPFC 
(40.3% versus 43.0%, respectively, p=0.022), but did not differ significantly between groups 
in the VMPFC (p=0.56). When the MRS measures were covaried for gray matter fraction, sex 
and age the study results remained unchanged. No significant diagnosis-by-sex interaction was 
identified. There was no significant difference in the creatine/NAA ratio between PD subjects 
and controls in either voxel (p>.1). The GABA levels did not differ between the seven 
PD+MDD subjects and controls, although the small sample size provided low power. 
 
Discussion 
These data constitute the first comparison of GABA concentrations in the PFC 
between unmedicated PD subjects and controls. The total GABA levels did not differ 
significantly between PD subjects and controls in the VMPFC or the DM/DALPFC. The PD 
subjects studied were either medication naïve (n=9) or unmedicated for >3months, and were 
matched subject-by-subject to the controls for age and gender(9).  
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Several methodological limitations merit comment. By requiring that subjects had not 
been exposed to psychotropic drugs for >3 months, the sample was biased toward cases with 
PD of moderate severity. In addition, the regional MRS data were normalized to local creatine 
concentrations using a conventional creatine referencing method(13,14), but creatine levels 
were not independently assessed. Massana et al.(10) previously reported that creatine levels 
were reduced in the right medial temporal lobe region in PD, although this study found no 
difference in creatine levels between PD patients and healthy controls in the medial PFC. 
Finally, the menstrual phase was not characterized in the females subjects. Epperson et 
al.(15,16) recently reported effects of menstrual cycle on MRS-GABA measures in the 
occipital cortex. However, we did not detect a difference in GABA levels in the VMPFC or 
DM/DALPFC between eight healthy women imaged in the follicular phase versus eight 
women in the luteal phase (Hasler and van der Veen, unpublished data).  
With 17 participants per group, an effect size (Cohen’s d) of .99 is needed to provide 
80% power to detect a difference at alpha=.05. Using paired t tests, this translates to a 
difference in GABA levels of 16% in the DM/DALPFC and 13% in the VMPFC given the 
variance measured in our study. In the DM/DALPFC, Cohen’s d was 0.0. In the VMPFC 
voxel, Cohen’s d was 0.23, but the direction of difference was in the direction opposite to that 
hypothesized. Consequently, the likelihood that our negative results were explained by Type-
II appeared low.  
Our results differed from those Ham et al.(3), who found reduced GABA levels in the 
anterior cingulate cortex in PD subjects versus controls. This region was encompassed within 
the VMPFC and DM/DALPFC voxels we placed, although the addition of more rostral PFC 
regions in our ROI would have diluted the effect of GABA levels from the cingulate cortex.  
Notably, all of the PD subjects studied by Ham et al. were receiving a combination of 
antidepressants and anxiolytics prior to scanning, while the PD subjects in our study were 
unmedicated. Since several classes of anxiolytic and antidepressant drugs alter central GABA-
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ergic transmission(17,18). The reduction in GABA levels reported in this previous study thus 
may have reflected the confounding effects of medications. 
Our study also did not extend the previously reported finding of reduced GABA levels 
in the occipital cortex(2) to the PFC. However, some differences between the Goddard et al. 
study(2) and our study exist which require investigation in future studies. Compared with our 
study, the subjects in Goddard et al. had more severe panic and depressive symptoms (mean 
PDSS and 25-item HAM-D scores in that study were 13 and 20, respectively). Since GABA 
levels appear reduced in the occipital and prefrontal cortices of patients with major depressive 
disorder(7,13,19), it is conceivable that the reduced GABA levels Goddard et al. observed in 
their PD sample may have reflected comorbid depression, although the GABA levels and 
depression ratings were not correlated significantly in Goddard et al. Finally, although 
treatment withdrawal effects may have influenced occipital cortex GABA levels in Goddard 
et al.(2) since they included PD subjects following a minimum of one-week medication 
washout, 9 of their 14 PD subjects were medication naïve, reducing the likelihood that such 
effects accounted for their findings. 
  Given alterations of the GABA-A receptor system in PD and the effects of rapid 
anxiolytic drugs on the GABAergic system, GABA-ergic function appears relevant to the 
pathophysiology of PD(6). The GABA concentration measured using MRS predominantly 
reflects intracellular, rather than intrasynaptic, GABA concentrations, as the majority of the 
GABA pool exists within GABAergic neurons(20). Thus while our methods did not address 
whether GABA neurotransmission in the PFC may be altered in PD, we found no abnormalities 
in the total intracellular GABA pool averaged over a broad PFC area.  
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Table 1.  Metabolite Concentrations (mmol/liter) in Prefrontal Brain Regionsa 
Voxel Subjects GABA Co-edited Glxc Choline NAA 
PD subjects (N=17) 0.98 (0.18) 2.57 (0.48) 1.59 (0.22) 10.32 (0.54) 
Healthy controls (N=17) 0.98 (0.25) 2.59 (0.48) 1.61 (0.32) 9.92 (0.99) 
DM/DALPFC b 
 
Statistics (df=16) 
 
t=0.07 
p=0.95 
t=0.13 
p=0.90 
t=0.31 
p=0.76 
t=-1.64 
p=0.12 
PD subjects (N=17) 0.98 (0.16) 2.65 (0.37) 1.49 (0.25) 9.59 (0.90) 
Healthy controls (N=17) 0.94 (0.18) 2.78 (0.43) 1.62 (0.20) 9.79 (0.64) 
VMPFC b 
Statistics (df=16) 
 
t=0.94 
p=0.36 
t=0.96 
p=0.35 
t=1.89 
p=0.08 
t=0.69 
p=0.50 
a The creatine concentration was set to 7.1 mmol/L. Metabolite concentrations are indicated as 
mean (standard deviation). 
b The DM/DALPFC voxel extended 5x3x2cm and was positioned with the posterior border 
abutting the anterior pole of the caudate nucleus, and the ventral border abutting the dorsal 
border of the putamen. The VMPFC voxel extended 3x3x2cm and was positioned with the 
posterior border abutting the rostrum of the corpus callosum, and was centered in horizontal 
planes on the midline and in sagittal planes on the bicommissural line. An image displaying 
the voxel positions within the brain appears in(8).  
c The co-edited Glx is proportional to the total Glx (see methods in (7)). The variation in Glx 
editing efficiency was estimated to be less than 22.9% based on the magnitude of the residual 
NAA signal in the edited subspectra. 
Abbreviations: DM/DALPFC, dorsomedial/dorsal anterolateral prefrontal cortex region-of-
interest; GABA, gamma-aminobutyric acid; Glx, glutamate/glutamine; NAA, N-acetyl 
aspartate; MDD, major depressive disorder; VMPFC, ventromedial prefrontal cortex region-
of-interest
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SUPPLEMENTAL MATERIAL 
 
Figure 1.  A typical set of GABA editing spectra obtained at 3 Tesla. a) is the unedited 
spectrum at TE=68 ms (number of unedited and edited scans=1024), NAA is visible; b) is the 
edited spectrum with the NAA region suppressed by the editing pulse; c) is the subtraction of 
a and b, resulting in the spectrum with the GABA and glx signals. The large negative NAA 
signal at 2.0 ppm is the result of the subtraction of the unedited signal with the positive NAA 
from the edited signal without the NAA signal. The Glx-2 signal at 3.8 ppm and the Glx-4 
signal at 2.4 ppm also were detected due to their J-coupling to Glx-3 at 2.1 ppm near the left 
edge and in the flat portion of the GABA editing pulse. The co-edited Glx-4 peak partially 
overlapped the negative NAA signal. However, the Glx-2 signal at 3.8 ppm was cleanly co-
edited, allowing simultaneous determination of Glx without GABA contamination. The edited 
GABA-4 signal was located at 3.0 ppm and was used for quantification of the GABA 
concentration. The co-edited GABA-2 signal at 2.3 ppm was largely overlapped by the 
residual Glx-4 signal at 2.4 ppm and the dominant NAA signal at 2.0 ppm. Excellent water 
and outer volume suppression were achieved. 
 
